Investigational drug · Phase 3
GQ1005
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for HER2-positive Breast Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Jun 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "GQ1005"
First trial start
2025
Jan 10, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GQ1005", any sponsor or status.
Conditions studied
As listed on its trial records.
- HER2-positive Breast Cancer
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "GQ1005" as an intervention, largest first.
- A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast CancerPivotal-lookingRecruiting
GeneQuantum Healthcare (Suzhou) Co., Ltd.Industry
NCT07673029 · 228 participants (planned) · Start Jan 10, 2025 · Primary completion Jan 9, 2027
Drug: GQ1005; T-DM1 · For: HER2-positive Breast Cancer
Sites: Bengbu, China; Fuyang, China; Hefei, China · 70 sites in all
GeneQuantum Healthcare (Suzhou) Co., Ltd.Industry
NCT06154343 · 150 participants (planned) · Start Nov 23, 2022 · Primary completion Dec 31, 2024
Drug: GQ1005 · For: HER2 Expressing or Mutated Advanced Malignant Solid Tumors
Sites: Beijing, China; Chongqing, China; Fuzhou, China · 20 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Site-specific ligase-dependent conjugation with ring-opening linker improves safety and stability of HER2-targeting ADCs.
Huang L, Qin G, Gong C, et al. · Nat Commun 2025
Also in development for HER2-positive Breast Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- DB-1303BNT323, trastuzumab pamirtecanPhase 35 trials
DualityBio Inc. · Metastatic Breast Cancer, HER2-positive Advanced Solid Tumor, Endometrial Cancer
- DP303cPhase 34 trials
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · HER2-positive Breast Cancer, Advanced Solid Tumors, Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
- IBI354Phase 33 trials
Innovent Biologics (Suzhou) Co. Ltd. · Locally Advanced Unresectable or Metastatic Solid Tumors, Ovarian, Primary Peritoneal
- A166Phase 32 trials
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Her 2 Positive Breast Cancer, HER2-positive Breast Cancer
- ZN-A-1041ZN-A-1041 Enteric, RO7771950Phase 32 trials
Roche (Genentech) · HER2-positive Breast Cancer, Advanced Solid Tumors
- HLX11Phase 31 trial
Shanghai Henlius Biotech · Breast Cancer, Breast Neoplasms, HER2-positive Breast Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.